Pediatrics

Your Article Summary

See Latest Articles

Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia
British Journal of Haematology, 06/08/09

Sutton R et al. – Study concludes a strong predictive value of minimal residual disease (MRD) kinetics at day 15; should be validated in a larger patient cohort so that earlier detection of risk of relapse can be assessed. In addition, data also provide evidence that additional late MRD monitoring of patients would enable detection of molecular relapse, which, in combination with salvage therapy, may provide the means to further improve survival rates in children with acute lymphoblastic leukaemia (ALL).

• Aim was to evaluate the prognostic significance of MRD at additional treatment phases
• MRD was measured by real-time qPCR on a selected group of 108 pts
• 36 pts with a bone marrow or central nervous system relapse and 72 matched pts in first remission

• MRD was prognostic of outcome at all five treatment phases tested: at day 15, day 35, 4, 12 and 24 mo
• Day 15 was the best early MRD time-point to differentiate between pts with high, intermediate and low risk of relapse
• MRD testing at 12 and particularly at 24 mo, detected molecular relapses in some pts up to 6 mo before clinical relapse

Today in Pediatric Heme/Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A therapeutic advances in Childhood Leukemia Consortium Study
Journal of Clinical Oncology, 10/22/09

Medulloblastoma in childhood: revisiting intrathecal therapy in infants and children
Cancer Chemotherapy and Pharmacology, 10/29/09

Genetics: Newborn screening for sickle cell anemia
Canadian Family Physician, 10/14/09

See All of Pediatric Heme/Oncology